FDA rolls out ex­pec­ta­tions for a loom­ing reg­u­la­to­ry shift for in­sulin and oth­er bi­o­log­ics

Cer­tain bi­o­log­ics will be re­moved from the FDA’s Or­ange Book on 23 March 2020 and in­clud­ed in the Pur­ple Book, and all sub­se­quent fol­low-on ap­pli­cants will not be able to re­ly up­on these new drug ap­pli­ca­tions for ap­proval but will have to win ap­proval as biosim­i­lars un­der new pro­posed rules on biosim­i­lar de­vel­op­ment.

The agency on Tues­day re­leased two new draft Q&A guid­ance doc­u­ments on biosim­i­lar de­vel­op­ment and the “deemed to be a li­cense” pro­vi­sion of the Bi­o­log­ics Price Com­pe­ti­tion and In­no­va­tion Act of 2009 (BP­CIA), as well as two fi­nal guid­ance doc­u­ments on the same top­ics and one pro­posed rule amend­ing the de­f­i­n­i­tion of a bi­o­log­i­cal prod­uct.

The ef­forts are part of the FDA’s decade-long work to be­gin — start­ing in March 2020 — tran­si­tion­ing the ap­proved mar­ket­ing ap­pli­ca­tions for a sub­set of bi­o­log­i­cal prod­ucts, such as in­sulin and hu­man growth hor­mone — which were pre­vi­ous­ly ap­proved as drugs un­der sec­tion 505 of the FD&C Act — to be deemed to be bi­o­log­ics li­cens­es.

The fi­nal guid­ance al­so de­scribes the FDA’s plans for sup­ple­ments to ap­proved NDAs that re­main pend­ing on 23 March 2020. “We in­tend to ad­min­is­tra­tive­ly con­vert these pend­ing NDA sup­ple­ments to pend­ing BLA sup­ple­ments un­der the PHS Act,” the agency said. In­dus­try pre­vi­ous­ly took is­sue with the FDA’s in­ten­tions on the mat­ter.

Got­tlieb Com­ments

While high­light­ing the need to bring down the price of in­sulin, FDA Com­mis­sion­er Scott Got­tlieb ex­plained at the CMS/FDA Sum­mit in Wash­ing­ton DC on Tues­day that the goal of the guid­ances and new poli­cies is two-fold: to min­i­mize spon­sors’ abil­i­ty to game the ex­clu­siv­i­ty pro­vi­sions and fore­stall biosim­i­lar en­try, and to make sure that when drugs tran­si­tion in­to bi­o­log­ics, they do not re­ceive ad­di­tion­al ex­clu­siv­i­ties that they are not en­ti­tled to.

In ad­di­tion to the guid­ance doc­u­ments and pro­posed rule, Got­tlieb ex­plained that the FDA is is­su­ing no­tice of how it will — up­on re­quest — re­view study pro­to­cols sub­mit­ted by biosim­i­lar ap­pli­cants to as­sess whether their pro­to­cols con­tain com­pa­ra­ble safe­ty pro­tec­tions to those in the risk eval­u­a­tion and mit­i­ga­tion strat­e­gy (REMS) for the prod­uct they’re try­ing to ref­er­ence — as ex­plained in the re­vised draft Q&A on biosim­i­lar de­vel­op­ment and the BP­CI Act.

“If re­quest­ed, the FDA will is­sue a let­ter to the ref­er­ence prod­uct hold­er in­form­ing them that com­pa­ra­ble pro­tec­tions ex­ist, and that the FDA won’t con­sid­er it to be a vi­o­la­tion of the brand­ed drug com­pa­ny’s REMS to pro­vide the biosim­i­lar spon­sor with a suf­fi­cient quan­ti­ty of the ref­er­ence prod­uct to per­form test­ing nec­es­sary to sup­port its biosim­i­lar ap­pli­ca­tion,” Got­tlieb said.

Rule and Guid­ance

New ques­tions in the re­vised draft Q&A al­so in­clude more in­for­ma­tion on the na­ture and type of in­for­ma­tion that a spon­sor should pro­vide to sup­port a post-ap­proval man­u­fac­tur­ing change for a li­censed biosim­i­lar prod­uct.

Oth­er new ques­tions, which the agency re­spond­ed no to, in­clude: “May a spon­sor seek ap­proval, in a 351(k) ap­pli­ca­tion or a sup­ple­ment to an ap­proved 351(k) ap­pli­ca­tion, of a route of ad­min­is­tra­tion, a dosage form, or a strength that is not the same as that of the ref­er­ence prod­uct?” and “May a spon­sor seek ap­proval, in a 351(k) ap­pli­ca­tion or a sup­ple­ment to an ap­proved 351(k) ap­pli­ca­tion, for a con­di­tion of use that has not pre­vi­ous­ly been ap­proved for the ref­er­ence prod­uct?”

The oth­er Q&A doc­u­ment fea­tures nu­mer­ous ques­tions and an­swers on biosim­i­lar­i­ty or in­ter­change­abil­i­ty, pro­vi­sions re­lat­ed to the re­quire­ment to sub­mit a BLA for a bi­o­log­i­cal prod­uct, and ex­clu­siv­i­ty.

The fi­nal and draft guid­ances on the “deemed to be a li­cense” pro­vi­sion spell out the tran­si­tion pe­ri­od for the bi­o­log­ics to which the pro­vi­sion ap­plies, how to iden­ti­fy prod­ucts sub­ject to the tran­si­tion, statu­to­ry or reg­u­la­to­ry re­quire­ments for BLAs, and tran­si­tion­ing bi­o­log­ics from the Or­ange to the Pur­ple Book.

The pro­posed rule, mean­while, would amend FDA’s reg­u­la­tion that de­fines “bi­o­log­i­cal prod­uct” to make a tech­ni­cal re­vi­sion and to con­form to the statu­to­ry de­f­i­n­i­tion en­act­ed in the BP­CIA.


Im­age: Scott Got­tlieb SHUT­TER­STOCK

First pub­lished here. Reg­u­la­to­ry Fo­cus is the flag­ship on­line pub­li­ca­tion of the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety (RAPS), the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care and re­lat­ed prod­ucts, in­clud­ing med­ical de­vices, phar­ma­ceu­ti­cals, bi­o­log­ics and nu­tri­tion­al prod­ucts. Email news@raps.org for more in­for­ma­tion.

Author

Zachary Brennan

managing editor, RAPS

John Hood [file photo]

UP­DATE: Cel­gene and the sci­en­tist who cham­pi­oned fe­dra­tinib's rise from Sanofi's R&D grave­yard win FDA OK

Six years after Sanofi gave it up for dead, the FDA has approved the myelofibrosis drug fedratinib, now owned by Celgene.

The drug will be sold as Inrebic, and will soon land in the portfolio at Bristol-Myers Squibb, which is finalizing a deal to acquire Celgene.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: AveX­is sci­en­tif­ic founder was axed — and No­var­tis names a new CSO in wake of an ethics scan­dal

Now at the center of a storm of controversy over its decision to keep its knowledge of manipulated data hidden from regulators during an FDA review, Novartis CEO Vas Narasimhan has found a longtime veteran in the ranks to head the scientific work underway at AveXis, where the incident occurred. And the scientific founder has hit the exit.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

Ab­b­Vie gets its FDA OK for JAK in­hibitor upadac­i­tinib, but don’t look for this one to hit ex­ecs’ lofty ex­pec­ta­tions

Another big drug approval came through on Friday afternoon as the FDA OK’d AbbVie’s upadacitinib — an oral JAK1 inhibitor that is hitting the rheumatoid arthritis market with a black box warning of serious malignancies, infections and thrombosis reflecting fears associated with the class.

It will be sold as Rinvoq — at a wholesale price of $59,000 a year — and will likely soon face competition from a drug that AbbVie once controlled, and spurned. Reuters reports that a 4-week supply of Humira, by comparison, is $5,174, adding up to about $67,000 a year.

The top 10 fran­chise drugs in bio­phar­ma his­to­ry will earn a to­tal of $1.4T (tril­lion) by 2024 — what does that tell us?

Just in case you were looking for more evidence of just how important Amgen’s patent win on Enbrel is for the company and its investors, EvaluatePharma has come up with a forward-looking consensus estimate on what the list of top 10 drugs will look like in 2024.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

ICER blasts FDA, PTC and Sarep­ta for high prices on DMD drugs Em­flaza, Ex­ondys 51

ICER has some strong words for PTC, Sarepta and the FDA as the US drug price watchdog concludes that as currently priced, their respective new treatments for Duchenne muscular dystrophy are decidedly not cost-effective.

The final report — which cements the conclusions of a draft issued in May — incorporates the opinion of a panel of 17 experts ICER convened in a public meeting last month. It also based its analysis of Emflaza (deflazacort) and Exondys 51 (eteplirsen) on updated annual costs of $81,400 and over $1 million, respectively, after citing “incorrect” lower numbers in the initial calculations.

The key dates for KRAS watch­ers through the end of the year — the trail is nar­row and risks are ex­treme

There’s nothing quite like a big patent win when it comes to burnishing your prospects in the pipeline. And for Amgen, which seems to have rescued Enbrel for a run to 2029, the cheering section on Wall Street is now fixed on AMG 510 and a key rival.

And it didn’t take much data to do it. 

There was the first snapshot of a handful of patients, with a 50% response rate. Then came word that Amgen researchers are also tracking responses in different cancers, at least one in colorectal cancer and appendiceal too. 

Bain's Or­ly Mis­han joins Pfiz­er's neu­ro spin­out Cerev­el; On­colyt­ic virus biotech taps Sil­la­Jen ex­ec He­le­na Chaye as CEO

→ Bain Capital is deploying one of its top investors to Cerevel Therapeutics, steering a $350 million-plus neuro play carved out of Pfizer. Orly Mishan — a co-founder and principal of Bain’s life sciences unit — was involved in the partnership that birthed the biotech spinout in the first place. As Cerevel’s first chief business officer, she is tasked with corporate development, program management as well as technical operations. 

UP­DAT­ED: Sci­en­tist-CEO ac­cused of im­prop­er­ly us­ing con­fi­den­tial in­fo from uni­corn Alec­tor

The executive team at Alector $ALEC has a bone to pick with scientific co-founder Asa Abeliovich. Their latest quarterly rundown has this brief note buried inside:

On June 18, 2019, we initiated a confidential arbitration proceeding against Dr. Asa Abeliovich, our former consulting co-founder, related to alleged breaches of his consulting agreement and the improper use of our confidential information that he learned during the course of rendering services to us as our consulting Chief Scientific Officer/Chief Innovation Officer. We are in the early stage of this arbitration proceeding and are unable to assess or provide any assurances regarding its possible outcome.

There’s no explicit word in the filing on what kind of confidential info was involved, but the proceeding got started 2 days ahead of Abeliovich’s IPO.

Abeliovich, formerly a tenured associate professor at Columbia, is a top scientist in the field of neurodegeneration, which is where Alector is targeted. More recently, he’s also helped start up Prevail Therapeutics as the CEO, which raised $125 million in an IPO. And there he’s planning on working on new gene therapies that target genetically defined subpopulations of Parkinson’s disease. Followup programs target Gaucher disease, frontotemporal dementia and synucleinopathies.

But this time Abeliovich is the CEO rather than a founding scientist. And some of their pipeline overlaps with Alector’s.

Abeliovich and Prevail, though, aren’t taking this one lying down.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

Chi­na has be­come a CEO-lev­el pri­or­i­ty for multi­na­tion­al phar­ma­ceu­ti­cal com­pa­nies: the trend and the im­pli­ca­tions

After a “hot” period of rapid growth between 2009 and 2012, and a relatively “cooler” period of slower growth from 2013 to 2015, China has once again become a top-of-mind priority for the CEOs of most large, multinational pharmaceutical companies.

At the International Pharma Forum, hosted in March in Beijing by the R&D Based Pharmaceutical Association Committee (RDPAC) and the Pharmaceutical Research and Manufacturers of America (PhRMA), no fewer than seven CEOs of major multinational pharmaceutical firms participated, including GSK, Eli Lilly, LEO Pharma, Merck KGaA, Pfizer, Sanofi and UCB. A few days earlier, the CEOs of several other large multinationals attended the China Development Forum, an annual business forum hosted by the research arm of China’s State Council. It’s hard to imagine any other country, except the US, having such drawing power at CEO level.